Ok Biotech Co Stock Fundamentals

4155 Stock   21.65  0.15  0.69%   
Ok Biotech Co fundamentals help investors to digest information that contributes to Ok Biotech's financial success or failures. It also enables traders to predict the movement of 4155 Stock. The fundamental analysis module provides a way to measure Ok Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ok Biotech stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Ok Biotech Co Company Current Valuation Analysis

Ok Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Ok Biotech Current Valuation

    
  3.01 B  
Most of Ok Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ok Biotech Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Ok Biotech Co has a Current Valuation of 3.01 B. This is 79.02% lower than that of the Healthcare sector and 75.75% lower than that of the Medical Devices industry. The current valuation for all Taiwan stocks is 81.88% higher than that of the company.

Ok Biotech Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Ok Biotech's current stock value. Our valuation model uses many indicators to compare Ok Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ok Biotech competition to find correlations between indicators driving Ok Biotech's intrinsic value. More Info.
Ok Biotech Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about  0.19  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Ok Biotech Co is roughly  5.15 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ok Biotech's earnings, one of the primary drivers of an investment's value.

4155 Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ok Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ok Biotech could also be used in its relative valuation, which is a method of valuing Ok Biotech by comparing valuation metrics of similar companies.
Ok Biotech is currently under evaluation in current valuation category among its peers.

4155 Fundamentals

About Ok Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ok Biotech Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ok Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ok Biotech Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for 4155 Stock Analysis

When running Ok Biotech's price analysis, check to measure Ok Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ok Biotech is operating at the current time. Most of Ok Biotech's value examination focuses on studying past and present price action to predict the probability of Ok Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ok Biotech's price. Additionally, you may evaluate how the addition of Ok Biotech to your portfolios can decrease your overall portfolio volatility.